Sixty-five per cent of patients on standard-dose heparin on ECMO had a severe bleed. Eleven per cent had a severe clot. And the heparin is there to prevent the eleven.
This is a journal club on RATE, published in The Lancet in July 2026: the first adequately powered randomised trial of anticoagulation intensity on ECMO. Three hundred and thirty adults on veno-venous or veno-arterial ECMO across seven Dutch intensive care units were randomised to standard-dose unfractionated heparin (APTT 2–2.5 times baseline), low-dose unfractionated heparin (1.5–2 times baseline) or therapeutic subcutaneous low-molecular-weight heparin.
We go through the question, the methods, the non-inferiority margin and what it actually means, and the results: both lower-intensity strategies were non-inferior, with no increase in thrombosis, no extra oxygenator changes, and a consistent but non-significant lean towards less bleeding and fewer deaths.
Then the critique — a composite endpoint dominated by death and bleeding, wide confidence intervals, a narrow definition of thrombosis, unstandardised APTT reagents, two thirds of ECMO patients never enrolled, and the practical problems with subcutaneous low-molecular-weight heparin in shocked patients — and the strengths.
Finally, what it means for us. Our unit already runs heparin at very low doses and reserves full anticoagulation for a specific indication such as pulmonary embolism; ECMO on its own isn't one. RATE draws the same line. And the practical point every resident should take away: blood products go through a peripheral drip, never the central line, because the oxygenator is downstream.
Chapters
- (00:00) Cold open — sixty-five against eleven
- (00:50) Why the standard target was never tested
- (02:05) Trial design and patients
- (02:30) Exclusions — and what they tell you
- (03:00) The three arms
- (04:00) The composite outcome
- (04:45) Statistics and the non-inferiority margin
- (05:40) Who was enrolled
- (06:30) Did the arms separate?
- (07:30) Primary outcome
- (08:00) Bleeding, thrombosis and mortality
- (08:50) Oxygenators and transfusion
- (09:15) Crossovers, tracheostomy and subgroups
- (09:55) Cost
- (10:10) Critique
- (12:10) Strengths
- (12:30) What it means for our practice
- (13:20) Blood products: peripheral, not central
- (14:15) Wider implications and anti-Xa targets
- (14:45) Three rules
Key takeaways
- The standard ECMO target — UFH to an APTT of 2–2.5 times baseline (about 60–75 s) — had never been tested in an adequately powered randomised trial
- RATE: 330 adults, VV and VA ECMO, seven Dutch ICUs; standard-dose UFH vs low-dose UFH (1.5–2 times baseline, about 45–60 s) vs therapeutic subcutaneous LMWH
- Primary composite (severe bleeding, severe thromboembolism, 6-month mortality): 81% vs 72% vs 75% — both lower-intensity strategies non-inferior
- Severe bleeding 65% vs 58% vs 59%; severe thromboembolism 11% vs 10% vs 9%; 6-month mortality 50% vs 42% vs 44% — all non-significant
- No increase in oxygenator changes or transfusion with lower-intensity anticoagulation
- Non-inferior is not superior: the confidence intervals are wide, and subgroup signals are hypothesis-generating only
- Thrombosis was probably undercounted, APTT reagents weren't standardised, and most ECMO patients in the participating units weren't enrolled
- Subcutaneous LMWH is less predictable in shocked, oedematous patients, accumulates in renal failure and can't be switched off quickly
- ECMO on its own is not an indication for full anticoagulation — reserve that for a specific indication such as PE, a mechanical mitral valve or intracardiac thrombus
- Give blood products through a peripheral drip, not the central line, to avoid sending a bolus of clotting factors straight onto the oxygenator
References / further reading
- van Minnen O, Oude Lansink-Hartgring A, van Amstel RBE, et al. Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial. Lancet 2026; published online July 7. doi:10.1016/S0140-6736(26)00851-2
- Martucci G, Giani M, Schmidt M, et al. Anticoagulation and bleeding during veno-venous extracorporeal membrane oxygenation: insights from the PROTECMO study. Am J Respir Crit Care Med 2024; 209: 417–26
- McMichael ABV, Ryerson LM, Ratano D, et al. 2021 ELSO adult and pediatric anticoagulation guidelines. ASAIO J 2022; 68: 303–10
Follow the podcast
Bluesky: @cardiacoutput.bsky.social
X: @CardiacOutputMC
If you've found this useful, a follow or a share genuinely helps other trainees find it — and do get in touch if there's a topic you'd like covered.
This podcast is for medical education for healthcare professionals. It is not clinical advice.